Forte Biosciences says FB102 hits statistically significant vitiligo improvement in Phase 1b trial at week 24

• Forte Biosciences reported statistically significant Phase 1b results for FB102 in vitiligo, showing a 29.6% mean FVASI improvement at week 24.
• Placebo-adjusted benefit was 21.7% in the efficacy-evaluable population (p=0.02); improvement was significant by day 64 (p=0.023).
• Patients with baseline FVASI ≥0.75 showed a 43.2% mean FVASI improvement at week 24 (p=0.006); FVASI50 reached 58.8%.
• Most treated patients kept improving through week 24 despite dosing ending at week 12; 84% improved, none worsened.
• Safety profile remained favorable, with mild to moderate adverse events similar to placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.